Substrate Hydrolysis by Matrix Metalloproteinase-9*

The catalytic clefts of all matrix metalloproteinases (MMPs) have a similar architecture, raising questions about the redundancy in substrate recognition across the protein family. In the present study, an unbiased phage display strategy was applied to define the substrate recognition profile of MMP-9. Three groups of substrates were identified, each occupying a distinct set of subsites within the catalytic pocket. The most prevalent motif contains the sequence Pro-X-X-Hy-(Ser/Thr) at P3 through P2′. This sequence is similar to the MMP cleavage sites within the collagens and is homologous to substrates the have been selected for other MMPs. Despite this similarity, most of the substrates identified here are selective for MMP-9 over MMP-7 and MMP-13. This observation indicates that substrate selectivity is conferred by key subsite interactions at positions other than P3 and P1′. This study shows that MMP-9 has a unique preference for Arg at both P2 and P1, and a preference for Ser/Thr at P2′. Substrates containing the consensus MMP-9 recognition motif were used to query the protein data bases. A surprisingly limited list of putative physiologic substrates was identified. The functional implications of these proteins lead to testable hypotheses regarding physiologic substrates for MMP-9.

[1]  A. Berger,et al.  On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.

[2]  G. P. Smith,et al.  Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. , 1985, Science.

[3]  H. Birkedal‐Hansen,et al.  Sequence specificity of human skin fibroblast collagenase. Evidence for the role of collagen structure in determining the collagenase cleavage site. , 1987, The Journal of biological chemistry.

[4]  J. Scott,et al.  Searching for peptide ligands with an epitope library. , 1990, Science.

[5]  J. Seltzer,et al.  Cleavage specificity of human skin type IV collagenase (gelatinase). Identification of cleavage sites in type I gelatin, with confirmation using synthetic peptides. , 1990, The Journal of biological chemistry.

[6]  M. Letarte,et al.  Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. , 1990, The Journal of biological chemistry.

[7]  Masayuki Amagai,et al.  Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion , 1991, Cell.

[8]  S. Shapiro,et al.  Human 92- and 72-kilodalton type IV collagenases are elastases. , 1991, The Journal of biological chemistry.

[9]  H. Birkedal‐Hansen,et al.  Sequence specificities of human fibroblast and neutrophil collagenases. , 1991, The Journal of biological chemistry.

[10]  T. Hardingham,et al.  The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. , 1992, The Journal of biological chemistry.

[11]  H. Birkedal‐Hansen,et al.  Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[12]  P. Roughley,et al.  Matrix metalloproteinases cleave at two distinct sites on human cartilage link protein. , 1993, The Biochemical journal.

[13]  H. Birkedal‐Hansen,et al.  Comparative sequence specificities of human 72- and 92-kDa gelatinases (type IV collagenases) and PUMP (matrilysin). , 1993, Biochemistry.

[14]  G. Opdenakker,et al.  Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein , 1993, Journal of neuroscience research.

[15]  G. Opdenakker,et al.  Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. , 1993, Biochemical and biophysical research communications.

[16]  Peter Roepstorff,et al.  Improved resolution and very high sensitivity in MALDI TOF of matrix surfaces made by fast evaporation , 1994 .

[17]  J. O'Connell,et al.  Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B. , 1994, The Journal of biological chemistry.

[18]  R. Huber,et al.  The X‐ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. , 1994, The EMBO journal.

[19]  M. Schaefer,et al.  Low Molecular Weight Inhibitors in Corneal Ulceration a , 1994, Annals of the New York Academy of Sciences.

[20]  D. Eyre,et al.  A 92 kDa gelatinase (MMP-9) cleavage site in native type V collagen. , 1994, Biochemical and biophysical research communications.

[21]  D. Kassel,et al.  Characterization of the peptide substrate specificities of interstitial collagenase and 92-kDa gelatinase. Implications for substrate optimization. , 1994, The Journal of biological chemistry.

[22]  L. Liotta,et al.  Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. , 1994, Biochemistry.

[23]  P. Reinemer,et al.  The metzincins — Topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a super family of zinc‐peptidases , 1995, Protein science : a publication of the Protein Society.

[24]  David R. Corey,et al.  Substrate Specificity of Tissue Type Plasminogen Activator , 1995, The Journal of Biological Chemistry.

[25]  H. Birkedal‐Hansen.  Proteolytic remodeling of extracellular matrix. , 1995, Current opinion in cell biology.

[26]  M. Navre,et al.  Rapid Identification of Highly Active and Selective Substrates for Stromelysin and Matrilysin Using Bacteriophage Peptide Display Libraries (*) , 1995, The Journal of Biological Chemistry.

[27]  D. Corey,et al.  Origins of the specificity of tissue-type plasminogen activator. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  R. Burgeson,et al.  LAD-1, the linear IgA bullous dermatosis autoantigen, is a novel 120-kDa anchoring filament protein synthesized by epidermal cells. , 1996, The Journal of investigative dermatology.

[29]  J. Seltzer,et al.  Comparison of cleavage site specificity of gelatinases A and B using collagenous peptides. , 1996, Biochimica et biophysica acta.

[30]  Z. Werb,et al.  Focalized proteolysis: spatial and temporal regulation of extracellular matrix degradation at the cell surface. , 1996, Current opinion in cell biology.

[31]  M. Karas.  Matrix-assisted laser desorption ionization MS: a progress report. , 1996, Biochemical Society transactions.

[32]  A. Shevchenko,et al.  Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. , 1996, Analytical chemistry.

[33]  Jeffrey W. Smith,et al.  Identification of a Region in the Integrin β3 Subunit That Confers Ligand Binding Specificity* , 1997, The Journal of Biological Chemistry.

[34]  I. Massova,et al.  Structural Insights into the Catalytic Domains of Human Matrix Metalloprotease-2 and Human Matrix Metalloprotease-9: Implications for Substrate Specificities , 1997 .

[35]  C. López-Otín,et al.  The Role of the C-terminal Domain of Human Collagenase-3 (MMP-13) in the Activation of Procollagenase-3, Substrate Specificity, and Tissue Inhibitor of Metalloproteinase Interaction* , 1997, The Journal of Biological Chemistry.

[36]  Z. Werb,et al.  Gelatinase B–deficient Mice Are Resistant to Experimental Bullous Pemphigoid , 1998, The Journal of experimental medicine.

[37]  Gabriele Bergers,et al.  MMP-9/Gelatinase B Is a Key Regulator of Growth Plate Angiogenesis and Apoptosis of Hypertrophic Chondrocytes , 1998, Cell.

[38]  L. Kappos,et al.  Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. , 1998, Brain : a journal of neurology.

[39]  D. Corey,et al.  Substrate specificity of prostate-specific antigen (PSA). , 1998, Chemistry & biology.

[40]  L. Kotra,et al.  Matrix metalloproteinases: structures, evolution, and diversification , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  Timo Sorsa,et al.  Tumor targeting with a selective gelatinase inhibitor , 1999, Nature Biotechnology.

[42]  W. Bode,et al.  Structural properties of matrix metalloproteinases , 1999, Cellular and Molecular Life Sciences CMLS.

[43]  K. Conant,et al.  Cerebrospinal fluid levels of MMP‐2, 7, and 9 are elevated in association with human immunodeficiency virus dementia , 1999, Annals of neurology.

[44]  G. Schneider,et al.  Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. , 1999, Science.

[45]  G. Fields,et al.  Hydrolysis of Triple-helical Collagen Peptide Models by Matrix Metalloproteinases* , 2000, The Journal of Biological Chemistry.

[46]  S. Shapiro,et al.  Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. , 2000, The Journal of biological chemistry.

[47]  Thiennu H. Vu,et al.  Matrix Metalloproteinase 9 and Vascular Endothelial Growth Factor Are Essential for Osteoclast Recruitment into Developing Long Bones , 2000, The Journal of cell biology.

[48]  L. Kotra,et al.  Characterization of the Monomeric and Dimeric Forms of Latent and Active Matrix Metalloproteinase-9 , 2000, The Journal of Biological Chemistry.

[49]  Z. Werb,et al.  The Serpin α1-Proteinase Inhibitor Is a Critical Substrate for Gelatinase B/MMP-9 In Vivo , 2000, Cell.

[50]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[51]  M. Weiner,et al.  Substrate Specificity of Human Collagenase 3 Assessed Using a Phage-displayed Peptide Library* , 2000, The Journal of Biological Chemistry.

[52]  J. Smith,et al.  A method for application of samples to matrix-assisted laser desorption ionization time-of-flight targets that enhances peptide detection. , 2000, Analytical biochemistry.

[53]  D. Hanahan,et al.  MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis , 2000, Cell.